{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:42:24Z","timestamp":1787244144637,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":354,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>H2FPEF and HFA-PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H2FPEF and HFA-PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this cohort study, 1068 HCM patients were included. Then the H2FPEF and HFA-PEFF scores were calculated to categorize patients into low, intermediate, and high score groups. The primary endpoint was a composite of the first HF hospitalization and all-cause death. 594 (55.6%) patients were classified discordantly. After a follow-up period of 3.1 \u00b1 2.1 years, 85 (8.0%) patients were admitted for HF for the first time, and 62 (5.8%) patients died. Rates of first HF hospitalization and all-cause death per 1000 person-years for the low, intermediate, and high H2FPEF score groups were 25.0 (95% confidence interval [CI]: 14.5\u201335.4), 52.0 (95% CI: 41.6\u201362.3), and 148.1 (95% CI: 77.7\u2013218.5), respectively. For the low-intermediate and high HFA-PEFF score groups, rates were 19.3 (95% CI: 11.6\u201327.0) and 69.3 (95% CI: 56.4\u201382.1), respectively. Intermediate H2FPEF score (hazard ratio [HR]: 1.820, 95% CI: 1.135\u20132.919; P = 0.013), high H2FPEF score (HR: 3.464, 95% CI: 1.774\u20136.765; P &amp;lt; 0.001), and high HFA-PEFF score (HR: 2.414, 95% CI: 1.501\u20133.882; P &amp;lt; 0.001) were each independently associated with an increased risk of the primary endpoint. Intermediate-high H2FPEF score demonstrated an equal risk for the primary endpoint compared to the high HFA-PEFF score (HR: 0.826, 95% CI: 0.636\u20131.072; P &amp;gt; 0.05). Obesity (HR: 1.958, 95% CI: 1.140\u20133.363; P = 0.015), atrial fibrillation (HR: 1.686, 95% CI: 1.071\u20132.654; P = 0.024), pulmonary hypertension (HR: 1.613, 95% CI: 1.032\u20132.521; P = 0.036) of the H2FPEF score, and the morphological major criterion (HR: 1.601, 95% CI: 1.084\u20132.364; P = 0.018) and functional major criterion (HR: 2.340, 95% CI: 1.442\u20133.797; P &amp;lt; 0.001) of the HFA-PEFF score were independent predictors of the primary endpoint. A new algorithm was constructed using the independent predictors from both scores, with the functional major criterion weighted as 2 points and the others as 1 point. The H2FPEF score, HFA-PEFF score, and the new algorithm demonstrated C-indices of 0.594, 0.651, and 0.681, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is discordance in the classification of patients with HCM using the H2FPEF and HFA-PEFF scores. Both scores demonstrated prognostic value in risk stratification for HF hospitalization and all-cause death in HCM patients. Future studies should develop and validate a new algorithm integrating both scores.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15247","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:30:18Z","timestamp":1741743018000},"page":"2225-2238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["H2FPEF and HFA-PEFF Scores for Heart Failure Risk Stratification in Hypertrophic Cardiomyopathy Patients"],"prefix":"10.1093","volume":"12","author":[{"given":"Yi-Peng","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Na","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ni","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-6855","authenticated-orcid":false,"given":"You-Bin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"2026021804274428000_ehf215247-bib-0001","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804274428000_ehf215247-bib-0002","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021804274428000_ehf215247-bib-0003","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"2024","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026021804274428000_ehf215247-bib-0004","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/eurheartj\/ehac764","article-title":"Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments","volume":"44","author":"Olivotto","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804274428000_ehf215247-bib-0005","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/ejhf.3413","article-title":"Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score","volume":"26","author":"Laenens","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0006","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026021804274428000_ehf215247-bib-0007","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0008","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026021804274428000_ehf215247-bib-0009","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","article-title":"Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community","volume":"8","author":"Selvaraj","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0010","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/ejhf.2616","article-title":"Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0011","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/ehf2.13096","article-title":"Prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation","volume":"8","author":"Ludwig","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0012","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/ehf2.13774","article-title":"HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation","volume":"9","author":"Seoudy","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0013","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ejhf.2142","article-title":"Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction","volume":"23","author":"Verbrugge","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0014","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021804274428000_ehf215247-bib-0015","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021804274428000_ehf215247-bib-0016","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021804274428000_ehf215247-bib-0017","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2026021804274428000_ehf215247-bib-0018","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021804274428000_ehf215247-bib-0019","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1540-8175.2011.01643.x","article-title":"Assessment of echocardiographic left atrial size: accuracy of M-mode and two-dimensional methods and prediction of diastolic dysfunction","volume":"29","author":"Stefano","year":"2012","journal-title":"Echocardiography"},{"key":"2026021804274428000_ehf215247-bib-0020","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014240","article-title":"Clinical implications of the New York Heart Association classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026021804274428000_ehf215247-bib-0021","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the Framingham study risk score functions","volume":"23","author":"Sullivan","year":"2004","journal-title":"Stat Med"},{"key":"2026021804274428000_ehf215247-bib-0022","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026021804274428000_ehf215247-bib-0023","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"2026021804274428000_ehf215247-bib-0024","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12574-020-00467-9","article-title":"The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy","volume":"18","author":"Mande\u015f","year":"2020","journal-title":"J Echocardiogr"},{"key":"2026021804274428000_ehf215247-bib-0025","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026021804274428000_ehf215247-bib-0026","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.echo.2011.05.009","article-title":"Tissue Doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy","volume":"24","author":"Kitaoka","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021804274428000_ehf215247-bib-0027","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.107.698985","article-title":"Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization","volume":"116","author":"Geske","year":"2007","journal-title":"Circulation"},{"key":"2026021804274428000_ehf215247-bib-0028","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2026021804274428000_ehf215247-bib-0029","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/ejhf.1646","article-title":"Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804274428000_ehf215247-bib-0030","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"2014","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2225\/66956306\/eschf_12_3_2225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2225\/66956306\/eschf_12_3_2225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:27:48Z","timestamp":1771406868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/2225\/8488367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15247","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"2024-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}